Pharmaceuticals - Indian - Bulk Drugs & Formln M/S
Particulars (in ₹ Cr.) | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
---|---|---|---|---|---|
Total Revenue | 850.23 | 685.33 | 568.56 | 465.27 | 508.08 |
Total Expenses | 758.29 | 669.29 | 625.46 | 560.52 | 577.77 |
Profit Before Tax | 91.95 | 55.25 | -56.90 | -95.25 | -69.69 |
Profit After Tax | 95.06 | 55.25 | -56.90 | -95.25 | -69.69 |
Operating Profit after Depreciation | 108.30 | 48.26 | -24.89 | -43.91 | -65.53 |
Particulars (in ₹ Cr.) | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
---|---|---|---|---|---|
Fixed Assets | 634.51 | 573.09 | 583.70 | 670.45 | 868.48 |
Total Non Current Assets | 763.12 | 724.20 | 712.91 | 687.39 | 890.58 |
Total Current Assets | 790.75 | 501.01 | 397.65 | 549.86 | 569.32 |
TOTAL ASSETS | 1,553.87 | 1,225.21 | 1,110.56 | 1,237.25 | 1,459.91 |
Total Shareholder's Fund | 1,169.47 | 688.65 | 647.38 | 652.91 | 765.98 |
Particulars (in ₹ Cr.) | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
---|---|---|---|---|---|
Net Cash from Operating Activities | 125.99 | 18.34 | 92.47 | 23.59 | 80.80 |
Net Cash used in Investing Activities | -312.03 | -31.21 | 112.94 | 67.21 | 167.11 |
Net Cash used in Financing Activities | 167.04 | 31.17 | -216.80 | -164.99 | -250.33 |
Particulars (in ₹ Cr.) | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
---|---|---|---|---|---|
Total Revenue | 849.76 | 685.33 | 565.98 | 457.16 | 505.49 |
Total Expenses | 758.23 | 669.29 | 618.75 | 553.03 | 593.94 |
Profit Before Tax | 91.52 | 55.25 | -52.77 | -95.87 | -88.46 |
Profit After Tax | 94.75 | 55.25 | -52.77 | -95.87 | -88.46 |
Operating Profit after Depreciation | 107.85 | 48.26 | -20.76 | -44.54 | -84.30 |
Particulars (in ₹ Cr.) | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
---|---|---|---|---|---|
Fixed Assets | 630.71 | 573.06 | 583.65 | 670.39 | 868.40 |
Total Non Current Assets | 769.91 | 729.46 | 711.12 | 682.22 | 885.22 |
Total Current Assets | 782.29 | 493.79 | 383.07 | 542.25 | 564.77 |
TOTAL ASSETS | 1,552.20 | 1,223.26 | 1,094.19 | 1,224.47 | 1,449.99 |
Total Shareholder's Fund | 1,218.32 | 731.96 | 677.95 | 681.34 | 797.83 |
Particulars (in ₹ Cr.) | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
---|---|---|---|---|---|
Net Cash from Operating Activities | 130.73 | 13.39 | 89.57 | 24.36 | 80.42 |
Net Cash used in Investing Activities | -315.81 | -26.70 | 112.93 | 67.21 | 167.12 |
Net Cash used in Financing Activities | 167.07 | 31.17 | -216.80 | -164.99 | -250.33 |
Particulars (in ₹ Cr.) | 2024-09 | 2024-06 | 2024-03 | 2023-12 | 2023-09 |
---|---|---|---|---|---|
Total Revenue | 222.70 | 244.41 | 217.10 | 220.59 | 198.76 |
Total Expenses | 192.36 | 211.92 | 188.18 | 185.20 | 175.44 |
Profit Before Tax | 25.90 | 28.12 | 30.39 | 30.20 | 20.04 |
Profit After Tax | 25.90 | 28.27 | 33.50 | 30.19 | 20.02 |
Operating Profit after Depreciation | 37.86 | 40.06 | 42.28 | 43.01 | 31.68 |
Particulars (in ₹ Cr.) | 2024-09 | 2024-06 | 2024-03 | 2023-12 | 2023-09 |
---|---|---|---|---|---|
Total Revenue | 222.70 | 244.41 | 217.10 | 220.59 | 198.76 |
Total Expenses | 193.11 | 211.16 | 188.18 | 184.67 | 175.06 |
Profit Before Tax | 25.62 | 29.11 | 29.95 | 30.55 | 20.24 |
Profit After Tax | 25.63 | 29.10 | 33.19 | 30.55 | 20.24 |
Operating Profit after Depreciation | 37.55 | 41.02 | 41.80 | 43.36 | 31.88 |
Company | Price | Market Cap (in ₹ Cr) |
---|---|---|
Orchid Pharma Ltd | ₹1,544.15 | ₹7,831.79 |
Sun Pharmaceuticals Industries Ltd | ₹1,761.80 | ₹4,22,714.84 |
Divis Laboratories Ltd | ₹5,818.40 | ₹1,54,460.24 |
Cipla Ltd | ₹1,427.30 | ₹1,15,270.75 |
Dr Reddys Laboratories Ltd | ₹1,288.45 | ₹1,07,511.36 |
Torrent Pharmaceuticals Ltd | ₹3,157.60 | ₹1,06,862.73 |
06 Nov 2024, 12:44 pm
10 Aug 2024, 12:49 pm
18 Jul 2024, 08:35 pm
29 Jun 2024, 10:08 am
28 Jun 2024, 07:23 pm